Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Chinese (SSE) Healthcare Sector Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies473
  • 7D0.3%
  • 3M-8.6%
  • 1Y10.1%
  • YTD-3.6%

The Healthcare industry has been flat over the last week, but Andon Health has lost 14%. The past year has been better, since the industry has gained 10% in that time. Looking forward, earnings are forecast to grow by 23% annually.

Sector Valuation and Performance

Has the Chinese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026CN¥6.3tCN¥2.3tCN¥148.6b38.5x42.5x2.7x
Sat, 14 Mar 2026CN¥6.2tCN¥2.3tCN¥147.9b39x42.2x2.7x
Mon, 09 Feb 2026CN¥6.5tCN¥2.3tCN¥146.0b41.7x44.3x2.8x
Wed, 07 Jan 2026CN¥6.6tCN¥2.3tCN¥145.1b40.2x45.2x2.9x
Fri, 05 Dec 2025CN¥6.5tCN¥2.3tCN¥145.1b38.8x44.6x2.8x
Sun, 02 Nov 2025CN¥6.8tCN¥2.3tCN¥144.0b41.4x47.3x3x
Tue, 30 Sep 2025CN¥6.7tCN¥2.2tCN¥142.6b39.6x47.3x3.1x
Thu, 28 Aug 2025CN¥6.9tCN¥2.2tCN¥144.7b40.1x47.5x3.1x
Sat, 26 Jul 2025CN¥6.6tCN¥2.2tCN¥150.0b39.4x43.7x3x
Mon, 23 Jun 2025CN¥5.8tCN¥2.2tCN¥150.0b34.2x38.7x2.6x
Wed, 21 May 2025CN¥5.8tCN¥2.2tCN¥150.1b34.9x38.7x2.6x
Fri, 18 Apr 2025CN¥5.5tCN¥2.2tCN¥156.7b31.3x35.3x2.5x
Sun, 16 Mar 2025CN¥5.8tCN¥2.2tCN¥153.9b33x37.7x2.6x
Tue, 11 Feb 2025CN¥5.6tCN¥2.2tCN¥153.8b32.2x36.5x2.5x
Thu, 09 Jan 2025CN¥5.3tCN¥2.2tCN¥153.7b30.5x34.7x2.4x
Sat, 07 Dec 2024CN¥6.0tCN¥2.2tCN¥153.7b34.9x38.9x2.7x
Mon, 04 Nov 2024CN¥5.7tCN¥2.2tCN¥153.9b31.8x37.3x2.6x
Wed, 02 Oct 2024CN¥6.1tCN¥2.2tCN¥161.8b35.2x37.4x2.7x
Fri, 30 Aug 2024CN¥4.9tCN¥2.3tCN¥164.4b27.3x30x2.2x
Sun, 28 Jul 2024CN¥5.0tCN¥2.3tCN¥166.8b27.4x30x2.2x
Tue, 25 Jun 2024CN¥5.2tCN¥2.3tCN¥164.9b28.4x31.6x2.3x
Thu, 23 May 2024CN¥5.9tCN¥2.3tCN¥167.5b31.4x35.1x2.6x
Sat, 20 Apr 2024CN¥5.5tCN¥2.3tCN¥174.9b29.3x31.7x2.4x
Mon, 18 Mar 2024CN¥6.0tCN¥2.3tCN¥178.6b31.4x33.8x2.6x
Wed, 14 Feb 2024CN¥5.7tCN¥2.3tCN¥179.8b27.4x31.5x2.5x
Fri, 12 Jan 2024CN¥6.2tCN¥2.3tCN¥176.8b33.3x34.9x2.7x
Sun, 10 Dec 2023CN¥6.6tCN¥2.3tCN¥178.2b35.6x37x2.9x
Tue, 07 Nov 2023CN¥6.6tCN¥2.3tCN¥176.7b35.4x37.6x2.9x
Thu, 05 Oct 2023CN¥6.5tCN¥2.3tCN¥185.2b33x34.9x2.8x
Sat, 02 Sep 2023CN¥6.2tCN¥2.3tCN¥186.5b32.2x33.2x2.7x
Mon, 31 Jul 2023CN¥6.7tCN¥2.3tCN¥193.1b34.1x34.6x2.9x
Wed, 28 Jun 2023CN¥6.5tCN¥2.3tCN¥191.9b34.1x34x2.9x
Fri, 26 May 2023CN¥7.0tCN¥2.3tCN¥191.7b36.7x36.4x3.1x
Sun, 23 Apr 2023CN¥7.1tCN¥2.3tCN¥236.3b36.9x29.9x3.1x
Price to Earnings Ratio

29.9x


Total Market Cap: CN¥7.1tTotal Earnings: CN¥236.3bTotal Revenue: CN¥2.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Healthcare Sector Price to Earnings3Y Average 37.4x202420252026
Current Industry PE
  • Investors are optimistic on the Chinese Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 42.5x which is higher than its 3-year average PE of 37.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 14% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Chinese Healthcare sector?

CN Market5.92%
Healthcare0.30%
Life Sciences5.21%
Healthtech3.08%
Biotech1.23%
Medical Equipment0.95%
Pharma-0.93%
Healthcare Services-1.26%
Industry PE
  • Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio of 95.2x.
    • Analysts are expecting annual earnings growth of 34.0%, which is higher than its past year's earnings decline of 9.8% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 95% over the next 5 years.
  • This is roughly in line with its past earnings growth rate.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
603259 WuXi AppTecCN¥106.833.0%
+CN¥9.2b		104.0%PE17.9x
002294 Shenzhen Salubris PharmaceuticalsCN¥67.274.7%
+CN¥3.3b		90.1%PE111.5x
603538 Ningbo Menovo PharmaceuticalCN¥55.5028.4%
+CN¥2.7b		317.3%PE123x
300347 Hangzhou Tigermed ConsultingCN¥59.055.4%
+CN¥2.6b		35.5%PE56.9x
688166 BrightGene Bio-Medical TechnologyCN¥57.6611.5%
+CN¥2.5b		49.0%PE446.9x

Latest News

688166
CN¥57.66
BrightGene Bio-Medical Technology
7D
11.5%
1Y
49.0%
603259
CN¥106.83
WuXi AppTec
7D
3.0%
1Y
104.0%

603259: Conviction List Inclusion And 2026 Guidance Will Shape Balanced Outlook

Analysts have adjusted their price target on WuXi AppTec to CN¥114.80 from CN¥123.00, reflecting updated views on revenue growth, profit margins, and a lower future P/E multiple following recent upgrades and the stock’s addition to an APAC conviction list. Analyst Commentary Recent research around WuXi AppTec highlights a mix of optimism and caution.
300677
CN¥52.74
Intco Medical Technology
7D
-9.1%
1Y
144.7%
300760
CN¥160.30
Shenzhen Mindray Bio-Medical Electronics
7D
-1.6%
1Y
-24.8%
300255
CN¥44.87
Hebei Changshan Biochemical Pharmaceutical
7D
5.0%
1Y
127.8%
603127
CN¥39.27
Joinn Laboratories(China)Co.Ltd
7D
9.2%
1Y
154.3%
688553
CN¥20.24
Sichuan Huiyu Pharmaceutical
7D
-16.1%
1Y
33.2%
688506
CN¥313.85
Sichuan Biokin PharmaceuticalLtd
7D
-2.5%
1Y
19.3%
301201
CN¥44.75
ChengDa Pharmaceuticals
7D
-28.7%
1Y
110.0%
002294
CN¥67.27
Shenzhen Salubris Pharmaceuticals
7D
4.7%
1Y
90.1%
300347
CN¥59.05
Hangzhou Tigermed Consulting
7D
5.4%
1Y
35.5%
002432
CN¥75.58
Andon Health
7D
-13.7%
1Y
103.7%
002082
CN¥28.41
Wanbangde Pharmaceutical Holding Group
7D
-18.4%
1Y
403.7%
600276
CN¥57.73
Jiangsu Hengrui PharmaceuticalsLtd
7D
0.5%
1Y
18.1%
600436
CN¥148.98
Zhangzhou Pientzehuang Pharmaceutical
7D
-2.5%
1Y
-28.7%
603538
CN¥55.50
Ningbo Menovo Pharmaceutical
7D
28.4%
1Y
317.3%